Advancements in Genetically Engineered Models for Precision Research
Key Growth Drivers and Opportunities
Rising Demand for Preclinical Studies: The growing demand for preclinical studies is significantly increasing the growth of the market model of mice, as laboratory mice are essential tools in evaluating new drugs and remedies before human tests. Pharmaceutical and biotechnology companies greatly rely on the models of mice to stimulate human diseases, test drug candidates and assess biological reactions in a controlled environment. There is a growing requirement of models of exact, reliable and genetically engineer mice, especially in oncology, neurology and genetic disorders, with R&D investment. This bounce in pregnancy research accelerates the demand for models of advanced and human-to-human mice, fuel the expansion of the market and innovation.
Challenges
The mice models face many boundaries in the market that can obstruct its growth and effectiveness. A major challenge is a biological difference between mice and humans, which can lead to incorrect predictions of human reactions to drugs or diseases, limiting the translation value of research. Additionally, moral concerns about animal testing, with strict regulatory guidelines, can restrict the experiment and increase research costs. High maintenance and reproductive costs, especially for models of genetically modified or human rats, also create financial obstacles for small research institutes. In addition, increasing availability of optional in in vitro and computational models can reduce dependence on animal models over time.
Innovation and Expansion
Researchers Created the First Completely Working Human Immune System Mouse Model
In July 2024, A biological research discovery offers fresh perspectives on disease modeling and immunotherapy development. Researchers at The University of Texas Health Science Center in San Antonio have developed a humanized mouse model that can mount certain antibody responses because it has a human immune system and a gut flora similar to that of humans. The multi-year effort, which was published in the August 2024 issue of Nature Immunology, aimed to build a humanized mouse with a fully functional human immune system in order to overcome the limits of the in vivo human models that are currently available.
The resultant humanized mice, known as TruHuX (for truly human, or THX), have a complete and functional human immune system, complete with lymph nodes, germinal centers, human T and B lymphocytes, memory B lymphocytes, thymus human epithelial cells, and plasma cells that produce highly specific antibodies and autoantibodies that are exactly like those found in humans.
The RenMice Series for Advanced Drug Discovery is Officially Launched by Biocytogen
In September 2023, The RenMice series, which consists of a set of independently created, completely human antibody mice and TCR mice with exclusive intellectual property, was formally disclosed by Biocytogen Pharmaceuticals Co., Ltd. As 'human,' the term 'Ren' is derived from the Chinese pinyin for '人' (rén), which incorporates Eastern cultural elements and symbolizes Biocytogen's dedication to creating cutting-edge technologies that promote the discovery, development, and delivery of novel therapeutics, ultimately improving human health.
RenMab, RenLite, RenNano, RenTCR, and RenTCR-mimic are the five strains of completely human antibody/TCR mice that make up the RenMice line. completely human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, completely human T-cell receptors (TCRs), and TCR-mimic antibodies have all been found using these animals.
Inventive Sparks, Expanding Markets
The key players operating in the mice model market include Charles River Laboratories, (US) The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Envigo (US), JANVIER LABS (France), genOway (France), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioservices (France), Ingenious Targeting Laboratory (US), Cyagen Biosciences (US), GVK BIO (India), The Andersons, Inc. (US), Innovive (US), Allentown, LLC (US), FENGSHI Group (China), Ozgene Pty Ltd. (Australia), and Harbour Biomed (US).
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
6 days ago
- Gizmodo
Diabetic Man With Gene-Edited Cells Produces His Own Insulin—No Transplant Drugs Required
A new case study offers a tantalizing glimpse into the potential future of transplantation medicine. A man with type 1 diabetes is now able to make his own insulin thanks to a transplant of gene-edited pancreatic cells—a transplant that hasn't required the typical drugs used to avoid rejection. Scientists in Sweden and the U.S. conducted the research, published this week in the New England Journal of Medicine. The 42-year-old man with long-standing diabetes was given donated islet cells that were genetically modified via CRISPR to prevent immune rejection. Roughly four months after the procedure, his fully gene-edited cells have continued to produce insulin without provoking an immune response. 'Our study, although preliminary, suggests that immune evasion is an alternative concept for the circumvention of allorejection,' the authors wrote in the paper. A New Diabetes Treatment Is on the Horizon—But It Involves Poop People with type 1 diabetes have immune systems that destroy the pancreatic cells responsible for making insulin. The condition can be managed with regular doses of synthetic insulin, but people's health still tends to worsen over time. Recently, scientists have been studying whether donated islet cell transplants can provide a self-sustained replacement supply of insulin for type 1 diabetics—an effective cure, in other words, provided the cells can survive long-term. Early clinical trials of the technology have looked promising so far, but these transplants still require lifelong immunosuppressive therapy to ensure the host's body doesn't go after the donated cells. Effective as these drugs are, they have their well-known drawbacks, such as weakening people's immunity to actual threats like infections. The study researchers have been experimenting with a unique approach to sidestep the need for these drugs. They first tested it on mice and monkeys, with this new case being the first test in humans. They created three specific edits in the donated cells, all intended to quiet the most likely responses from the immune system. Two of the edits deplete the cells' supply of HLA class I and II antigens, proteins that tell our T cells whether another cell is foreign or not. A third edit causes the donated cells to make more of another protein called CD47 that inhibits the activity of other immune cells that would normally target them. The researchers injected the modified cells into the man's forearm. The edits weren't completely successful in some of the cells, and the man's immune system quickly killed off these cells. But as hoped, his body left the fully edited cells alone, even without immunosuppressants. The surviving cells produced insulin as normal, and the man appeared to be doing well 12 weeks later. He did experience several adverse events, but none were serious or linked to the transplanted cells themselves (he had mildly inflamed veins where a catheter was placed, for instance). This study is only a proof of concept, geared more at showing the procedure can be done safely than at proving it actually works. The man was given a relatively low dose of the donated cells, likely too low for his body to produce enough insulin on its own to no longer need treatment. Follow-up is also needed to know whether these cells can survive long-term. In Medical First, Woman's Type 1 Diabetes Seemingly Cured by Stem Cells But there's much to be encouraged about. And it's the latest sign that scientists are truly on the verge of making type 1 diabetes curable. Other research teams have shown early success in using similar transplants to cure the condition, including some that have also avoided needing immunosuppressant therapy.
CNBC
06-08-2025
- CNBC
Candy giant Mars partners with biotech firm to gene-edit cocoa supply
Candy maker Mars said Wednesday it's partnered with biotech company Pairwise to speed up the development of more resilient cocoa using CRISPR-based gene editing technology. The agreement gives the M&M's maker access to Pairwise's Fulcrum platform, which includes a library of plant traits, and gives Mars the ability to tailor its crops to be stronger and more sustainable. CRISPR is a gene editing tool that makes fast and precise changes to DNA. In farming, it's used to improve crops by targeting different traits like drought and disease resistance. The goal is to create cacao plants — the source of cacao beans, which are then roasted and made into cocoa — that can better withstand disease, heat and other climate-related stresses that can put global chocolate supply at risk. In October, Starbucks invested in two innovation farms in Central America to protect the chain's coffee supply from global warming. The farms develop climate-resilient coffee and test technologies like drones and mechanization. Gene editing allows for faster and more precise trait development than traditional breeding, Pairwise said in a press release. CRISPR has garnered attention in recent years for its applications in health care. In late 2023, the U.S. Food and Drug Administration approved the first gene-editing treatment for sickle cell disease. "At Mars, we believe CRISPR has the potential to improve crops in ways that support and strengthen global supply chains," said Carl Jones, Plant Sciences Director at Mars, in the release. Last month, the candy giant announced a $2 billion investment in U.S. manufacturing through 2026. This includes a new $240 million investment for a Nature's Bakery facility in Utah.
Yahoo
06-08-2025
- Yahoo
Mars and Pairwise Collaborate to Accelerate Cacao Research and Development
Durham, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mars, Incorporated has licensed Pairwise's Fulcrum® gene editing tools for cacao research and development. This licensing agreement grants Mars access to Pairwise's CRISPR tools, including the SHARC™ enzyme. The Pairwise Fulcrum platform encompasses gene editing tools, enzymes and trait libraries, enabling precise changes that unlock the plant's inherent potential. This capability significantly accelerates the development of impactful crop traits compared to traditional breeding methods, allowing for the activation or deactivation of characteristics and fine-tuning traits, much like adjusting a dimmer switch to achieve optimal results. Mars aims to develop this advanced plant breeding technology to improve cacao production and effectively tackle agricultural challenges. The ultimate goal is to help address the pressures cacao faces globally from climate variability, plant diseases and environmental stresses. This strategic initiative underscores the potential of this technology to drive meaningful advancements in agriculture. "At Mars, we believe CRISPR has the potential to improve crops in ways that support and strengthen global supply chains," said Carl Jones, Plant Sciences Director at Mars. "Our focus is to transparently and responsibly conduct CRISPR research in plant science that helps crops better adapt to climate challenges, disease pressures and resource constraints." "We're pleased to provide Mars with access to our Fulcrum platform for their cacao research and development initiatives," said Ian Miller, Chief Operating Officer at Pairwise. "Plant breeding innovation has the potential to help address important agricultural challenges, and we look forward to supporting Mars' research goals." The Pairwise Fulcrum platform includes gene editing tools, enzymes and trait libraries, enabling precise changes that unlock the plant's inherent potential to greatly accelerate the development of impactful crop traits compared to traditional breeding methods.### About Pairwise Pairwise is agriculture's gene editing powerhouse, building a healthier world through partnership and plant innovation. Co-founded by the inventors of CRISPR, our Fulcrum® Platform accelerates the development of climate-resilient, nutritious, and sustainable crops. As trusted partners to global industry leaders and nonprofit institutions, we help breeders move faster while transforming food and agriculture for farmers, consumers, and the planet. Founded in 2017 and based in Durham, NC, Pairwise is committed to delivering innovation that makes food easier to grow and better to eat. For more information, visit CONTACT: Communications Pairwise communications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
